deltatrials
Completed PHASE1/PHASE2 NCT00077012

Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia

A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Transurethral Photodynamic Therapy With QLT0074 for Benign Prostatic Hyperplasia

Sponsor: QLT Inc.

Conditions Benign Prostatic Hyperplasia
Interventions Photodynamic therapy QLT0074
Updated 6 times since 2017 Last updated: May 22, 2012 Started: Mar 31, 2003 Primary completion: May 31, 2005 Completion: May 31, 2005

Listed as NCT00077012, this PHASE1/PHASE2 trial focuses on Benign Prostatic Hyperplasia and remains completed. Sponsored by QLT Inc., it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • QLT Inc.
Data source: QLT Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dallas, United States
  • • Montreal, Canada
  • • Myrtle Beach, United States
  • • New Port Richey, United States
  • • San Francisco, United States
  • • Vancouver, Canada
  • • Washington D.C., United States